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Abstract  
Psychological stress is common in many physical illnesses and is increasingly recognized as 
a risk factor for disease onset and progression. An emerging body of literature suggests that 
stress has a role in the aetiology of type 2 diabetes mellitus (T2DM) both as a predictor of 
new onset T2DM and as a prognostic factor in people with existing T2DM. Here, we review 
the evidence linking T2DM and psychological stress. We highlight the physiological 
responses to stress that are probably related to T2DM, drawing on evidence from animal 
work, large epidemiological studies and human laboratory trials. We discuss population and 
clinical studies linking psychological and social stress factors with T2DM, and give an 
overview of intervention studies that have attempted to modify psychological or social factors 
to improve outcomes in people with T2DM. 
 
 
 
 
 
 
 
 
 
 
Key points  
• Psychological stress mobilizes biological responses implicated in type 2 diabetes 
mellitus (T2DM), including the release of glucose and lipids into the circulation, 
inflammatory cytokine expression and increased blood pressure  
• Repeated or sustained stress exposure leads to chronic allostatic load, with 
dysregulation of glucose metabolism and neuroendocrine function and chronic low 
grade inflammation. Dysregulation of the diurnal profile of cortisol release predicts 
incident T2DM in population studies  
• Epidemiological studies implicate depression, chronic work stress and early life 
adversity as risk factors for T2DM  
• The adverse effect of psychological stress on health behaviours such as food choice, 
physical activity and adherence to medication also contributes to T2DM risk  
• Among individuals with established diabetes mellitus, depression and diabetes 
mellitus-related distress are associated with poor glycaemic control and 
cardiovascular complications  
• Stress management interventions seem to alleviate stress symptoms in T2DM, but 
effects on disease progression have not been established  
 
 
 
 
 
 
When faced with a threat, animals and humans respond rapidly with sympathetic nervous 
system activation coupled with upregulation of the hypothalamic–pituitary– adrenal (HPA) 
axis1, 2, which results in increased release of the glucocorticoid cortisol from the adrenal 
cortex (FIG. 1). Corticotropin-releasing hormone, which is released from the hypothalamus 
in response to stress, activates the HPA axis and stimulates the release of adrenocorticotropic 
hormone from the pituitary gland into the systemic circulation. The principle target of 
adrenocorticotropic hormone is the adrenal cortex, where it stimulates the release of cortisol, 
a glucocorticoid hormone. Cortisol has vital physiological functions, many of which are 
relevant to diabetes mellitus; indeed, glucocorticoid hormones are so named owing to their 
influence on glucose homeostasis3.  
In response to stress, cortisol promotes the mobilization of energy stores, which induces the 
release of glucose and lipids into the circulation. The release of cortisol suppresses 
inflammatory responses and stimulates the cardiovascular system, which increases blood 
pressure by working with the sympathetic system1, 2. The sympathetic nervous system 
innervates multiple tissues, and acts in conjunction with the release of adrenaline from the 
adrenal medulla to increase heart rate and blood pressure, decrease heart rate variability and 
induce energy mobilization and the release of pro-inflammatory cytokines1, 2.  
Psychological stress is an umbrella term that encompasses a range of phenomena. It can 
include exposure to stressful conditions such as work stress, psychological distress, including 
emotional disorders like depression and anxiety, as well as negative personality traits such as 
anger or hostility. The physiological response to psychological stress is adaptive and 
designed to mobilize the organism for action and bolster immune mechanisms. Allostasis is 
the term used to describe this dynamic regulatory process whereby the maintenance of 
homeostasis occurs through the production of mediators such as adrenaline and cortisol. In 
the context of diabetes mellitus, glucose allostasis refers to the feedback loop that controls 
glucose metabolism. This regulatory process maintains glucose concentrations in a narrow 
range such that an increase in levels of glucose usually causes a corresponding increase in 
insulin secretion to restore equilibrium4. Allostatic load refers to the repeated or sustained 
stimulation of an allostatic system through exposure to psychological stress, which ultimately 
results in a regulatory system failing to operate within adaptive limits. In the context of type 2 
diabetes mellitus (T2DM), overabundance of glucose or lipids relative to cellular energy 
demands constitutes a form of metabolic stress that can promote insulin resistance and weight 
over time7. Components of the biological response to stress that plausibly contribute to 
T2DM include dysregulation of the cardiovascular system, changes in neuroendocrine 
parameters, such as cortisol, and heightened inflammation.  
Here, we focus on psychological stress as a modifiable risk factor for T2DM, as stress in 
T1DM is a separate issue8. This Review aims to summarize the evidence linking T2DM and 
psychological stress, with a focus on the physiological processes involved.  
 
Stress-related processes and T2DM  
Animal studies. 
 Studying the relationship between stress and disease outcomes in humans is somewhat 
limited, as randomization to chronic stress exposure and comparison conditions is not ethical. 
Animal models therefore offer a useful methodology to help to understand the pathways 
linking chronic stress and stress-related biological processes with T2DM. Corticosterone is 
the primary glucocorticoid involved in the rodent physiological stress-response system9. 
Chronic administration of corticosterone in drinking water leads to hyperglycaemia, insulin 
resistance and dyslipidaemia in rodents10, 11. Feeding with a high-fat diet might exacerbate the 
effects of chronic administration of glucocorticoid12, which is interesting considering that 
changes in eating behaviour are a potential response to chronic stress in 
humans13. Conversely, removal of the adrenal gland in rodents sensitizes the brain to insulin, 
suggesting that the absence of circulating glucocorticoids improves insulin sensitivity14.  
Researchers have developed several animal models to study the link between early life 
stress and diabetes-related parameters in animals. In rodents, some evidence suggests that 
brief maternal separation in the neonatal period is associated with heightened levels of 
glucose and insulin15, 16; however, others have reported that fragmented nesting behaviour in 
early life has no effect on levels of glucose and insulin, and could even improve insulin 
sensitivity17, 18. The type, severity and length of the stress exposure could account for these 
varying results. For example, varied methods were used to gain5. Chronically heightened 
levels of glucose can damage mitochondria and mitochondrial DNA, which in turn can 
promote inflammation and telomere shortening6.  
Chronic activation of the biological systems involved in stress response can promote 
dysregulated physiological reactivity, resulting in heightened, prolonged or diminished 
responses to stress, increasing vulnerability to disease and contributing to negative health 
outcomes induce stress, including maternal separation15,16,18, as well as limited access to 
nesting materials17. Furthermore, in the studies that used maternal separation stress15–17, the 
length of separation varied from 10 min per day15, 16 to 180 min18 per day for up to 21 days. 
The characteristics of the rodents used in the different studies also varied. Some studies used 
males rats15, 16, and others females rats17, 18, some rats assessed from birth15, 16, and others from 
day 2 of life17. The breeds used also varied, with CD-115, 16, Sprague Dawley17 and Wistar18 
rats included across the different studies.  
The notion that one period of stress exposure in early life might not be sufficient to induce 
metabolic change was noted in a 2015 study, which induced stress using footshock. The 
authors reported that early life stress at 2 weeks of age did not affect glucose and insulin 
parameters in rats; however, when this stress was combined with a second bout of stress at 8–
10 weeks of age, levels of glucose and insulin were observed to increase, and insulin 
sensitivity and glucose tolerance became poorer19. In bonnet macaques, difficulty in foraging 
and obtaining food during nursing is used as a model of early life stress20. Under this 
procedure when offspring are 3–5 months old, the mothers are exposed to scenarios in which 
the effort to access food alternates from easy to difficult over a period of 16 weeks. 
Compared with normally reared monkeys, those exposed to this form of juvenile stress have 
significantly greater body weight and waist circumference, as well as impaired insulin 
resistance as measured using a glucose clamp21.  
In summary, chronic administration of glucocorticoids leads to hyperglycaemia and insulin 
resistance in rodents, whereas the evidence for early life stress causing changes in metabolic 
parameters is mixed. One explanation for the conflicting data is that several stress exposures 
are necessary to induce changes in levels of insulin and glucose in rodents. In bonnet 
macaques, research suggests that stress related to food availability early in life reduces insulin 
sensitivity.  
 
Human epidemiological studies.  
Investigators can use observational cohort studies to study the relationship between stress-
related biological processes and diabetes in humans; however, one should note that not all 
biological processes lend themselves to being studied in large population studies owing to 
sampling difficulty and expense. Numerous pathways, through which stress-related biological 
processes act, have been hypothesized to contribute to T2DM aetiology (FIG. 2).  
Chronic activation of the HPA axis can lead to dysregulated cortisol output22. Furthermore, 
neuroendocrine dysfunction has been implicated in the pathogenesis of T2DM; 
glucocorticoid receptors are expressed on pancreatic β cells, and cortisol stimulation directly 
influences insulin sensitivity and decreases insulin secretion23. Patients with long-term 
cortisol excess, as seen in those with Cushing syndrome24, and patients treated with 
glucocorticoids often have increased susceptibility to hyperglycaemia and manifest diabetes 
mellitus25. Early research investigating the link between neuroendocrine dysfunction and 
diabetes mellitus assessed levels of plasma cortisol from single samples26, 27; however, corti-
sol shows marked circadian and diurnal rhythms that are better captured with multiple 
samples across the day28.  
The pattern of daily cortisol release is characterized by high levels of cortisol on waking, 
followed by an increase that reaches a peak 30–45 min after waking (termed the cortisol 
awakening response (CAR)) and subsequent decline over the day28 (FIG. 3). Dysregulation 
of the HPA axis can cause a reduction in the amplitude of the diurnal cortisol pattern or a 
flatter slope in the decline of levels of cortisol across the day28. Dysregulation in cortisol 
secretion can result in changes to the marked increase in cortisol concentrations after 
waking29. The CAR and the slope are thought to reflect separate neurobiological control sys-
tems; therefore, experimental samples of cortisol taken 30 min after waking, which reflect the 
CAR, are conventionally not included when calculating the cortisol slope28.  
Several studies have investigated the cross-sectional association between diurnal cortisol 
release and T2DM. The largest study to date, which included over 3,500 individuals from the 
Whitehall II epidemiological cohort, reported that people with T2DM had a flatter slope in 
levels of cortisol across the day and raised evening concentrations of cortisol compared with 
healthy individuals30, which corroborates previous evidence from another community cohort 
study31. Elevated levels of cortisol in the evening are associated with increased mortality risk 
from cardiovascular disease32. However, other findings in the area have been inconsistent33–
35, with two studies reporting a lower CAR in participants with T2DM than in controls33, 34 but 
no association with the cortisol slope33, and the other study finding no association between 
T2DM and any cortisol parameter across the day35. Differences in study samples or in the 
timing or number of cortisol samples might account for these conflicting findings. Few 
studies have linked neuroendocrine dysfunction with future changes in glucose metabolism. 
To the best of our knowledge, only one study has examined the relationship between the 
complete diurnal cortisol profile, which is morning cortisol, the CAR, the cortisol slope and 
evening cortisol and incident T2DM in an initially healthy population36. In this analysis of 
3,270 initially healthy individuals from the Whitehall II cohort, raised evening levels of 
cortisol predicted new onset T2DM over a 9 year follow-up period independent of covariates. 
When the analysis was expanded to a broader category of glucose disturbance to include 
prediabetes, raised evening concentrations of cortisol and a flatter slope in cortisol across the 
day were found to predict the combined outcome. No associations were detected between 
morning levels of cortisol or the CAR and T2DM onset.  
Another mechanism by which stress might influence the risk of developing diabetes 
mellitus is through activation of the immune system. T2DM has been characterized as a 
chronic low-grade inflammatory state involving multiple inflammatory mechanisms and 
metabolic pathways37. Obesity is common in patients with T2DM, and visceral adipose tissue 
is a major source of inflammatory factors — collectively termed adipokines38 — that include: 
cytokines such as C-reactive protein (CRP); IL-6; IL-1β; tumour necrosis factor; and 
hormone-like factors such as leptin, adiponectin, resistin, chemokines and acute phase 
proteins38. Adipokines are released into the circulation to affect many tissues including the β 
cells of the pancreas, which in turn affects insulin sensitivity39, 40.  
Data from epidemiological studies indicate that circulating concentrations of pro-
inflammatory adipokines are elevated in patients with T2DM. For example, a German study 
of over 15,000 individuals documented a dose– response relationship between impaired 
glucose status and adipokine concentrations41. Increased concentrations of inflammatory 
cytokines are also predictive of the development of T2DM in initially healthy populations. 
Prospective studies indicate that raised concentrations of IL-6 and CRP in the circulation are 
associated with increased risk of future T2DM42.  
Taken together, the observational evidence supports a link between T2DM and 
inflammation. However, causality cannot be determined from observational studies owing to 
potential issues of confounding and reverse causality. Another type of epidemiological study 
known as Mendelian randomization uses the properties of common genetic variation (random 
allocation of alleles at the time of conception) to estimate the causal contribution of a 
biological factor of choice with disease outcomes43. One large study reported a near 
significant effect (P = 0.06) of a functional variant causing impaired signalling at the IL-6 
receptor with reduced risk of developing diabetes mellitus44. Studies investigating variants in 
the genes that encode CRP and IL-1 have not detected statistically significant associations 
with T2DM45. This area of research has not yet been widely investigated, and thus future 
studies might detect associations45. 
Stress-induced sympathetic activation of the autonomic nervous system causes changes in 
blood pressure, heart rate and cardiac output, whereas parasympathetic activation results in 
changes in heart rate variability. High blood pressure is a recognized risk factor for diabetes 
mellitus46. For example, a 2015 study investigated the link between objectively measured 
blood pressure and risk of diabetes mellitus using linked electronic health records from a UK 
primary care population47. In this cohort of 4.1 million adults who did not have diabetes 
mellitus or cardiovascular disease at baseline, both systolic and diastolic blood pressure were 
found to have a dose–response relationship with the risk of developing diabetes mellitus, 
independent of a range of covariates. The paper also included a meta-analysis of 30 
previously published prospective studies. The pooled results indicated that, for an increase of 
20 mmHg in systolic blood pressure, the relative risk of diabetes mellitus was 1.77 (95% CI 
1.53–2.05). Proposed pathways through which blood pressure might increase the risk of 
diabetes mellitus include insulin resistance47 and inflammation48 (FIG. 2).  
Raised resting heart rate is also a hypothesized risk factor for new onset T2DM. A review 
of 10 cohort studies, which included almost 120,000 participants, found a dose–response 
relationship between resting heart rate and incident T2DM, with a 19% increased risk of 
T2DM for every 10 beats per min increment in resting heart rate49. As resting heart rate is a 
marker of autonomic regulation, an imbalance between the sympathetic and parasympathetic 
nervous systems might contribute to the association between increased heart rate and diabetes 
mellitus. Autonomic regulation is also associated with inflammation and components of the 
metabolic syndrome, such as central fat accumulation50, 51, all of which increase T2DM risk. 
A bidirectional association exists between inflammation and autonomic function in the 
context of the metabolic syndrome. Reduced heart rate variability, a marker of autonomic 
regulation, is associated with increased fasting glucose, increased cortisol and expression of 
pro-inflammatory cytokines52, whereas inflammation contributes to vasoconstriction and 
sodium retention in the context of stress-related high blood pressure53. 
 
   Evidence from epidemiological studies with repeated measures of glucose and insulin 
parameters over many years suggests that the development of T2DM is a gradual process54, 
55. For example, data from over 6,500 initially healthy individuals suggest that fasting levels 
of glucose and post-load glucose concentrations are higher among individuals who develop 
T2DM than in those who do not develop it up to 13 years before disease onset55. The glucose 
values of the incident T2DM cases increased in a linear manner (average fasting value of 5.47 
mmol/l at baseline), until 2–6 years before T2DM diagnosis when abrupt elevations in 
glucose concentrations (average fasting value ranging from 5.79 mmol/l 3 years before 
diagnosis to 7.40 mmol/l at the end of follow-up) were observed. In the control participants 
who did not develop T2DM, glucose parameters increased slightly over time (average fasting 
value of 5.26 mmol/l at baseline, increasing to 5.31 mmol/l at the end of follow-up) but no 
abrupt rises in concentrations were detected. Individuals who developed T2DM had lowered 
insulin sensitivity at baseline and showed a marked decrease in insulin sensitivity in the 5 
years before onset of the disease. These participants also had elevated insulin secretion until 
3–4 years before diagnosis when the levels of insulin declined steeply. Conversely, control 
participants did not experience a change in insulin parameters during the study period.  
As previously mentioned, changes in many stress-responsive biological systems influence 
glucose metabolism and insulin release; however, importantly, glucose and insulin are 
themselves stress responsive5, 56. Therefore, chronic psychological stress can act directly on 
glucose and insulin parameters, as well as affecting these processes indirectly through the 
other pathways discussed in this Review.  
 
Human laboratory stress studies and allostatic load.  
   Epidemiological studies investigating the link between stress-related biological processes 
and T2DM have for the most part focused on single system measures of stress, such as 
cardiovascular measures alone, inflammatory markers alone or HPA axis measures alone. 
However, the stress response is dynamic and involves multiple biological processes. 
Repeated stimulation of the stress system as a result of chronic stress is thought to lead to 
dysregulation across several inter-related systems22. Typically, the concept of allostatic load 
is quantified by assessing a range of biomarkers, including cardiovascular, inflammatory and 
neuroendocrine measures, as well as glucose metabolism and anthropometric measures, but 
available evidence on T2DM is mixed. One study of 1,000 individuals reported that high 
allostatic load was associated with increased T2DM risk57; however, another investigation of 
53 individuals failed to detect an association58.  
  Both aforementioned studies assessed allostatic load using biological measures taken at rest, 
which could present an issue. Allostasis is a dynamic process, and it manifests in response to 
challenge22, whereby a brisk biological activation occurs as the body mobilizes to deal with 
the stressor, a process that is followed by a swift recovery back to baseline values. Allostatic 
load dysregulates this dynamic process, which can result in inadequate biological responses 
to stress, with failure to mount an appropriate stress response and/or poor stress recovery, 
with diminished ability to return to pre-stress values across various parameters7, 22.  
To study stress-induced changes across multiple biological systems, investigators can use 
acute laboratory stress testing. To date, only a single study has investigated the dynamics of 
the multiple systems that are potentially involved in the stress–diabetes mellitus rela-
tionship59. In the analysis, 140 individuals with T2DM and 280 healthy controls who were 
matched for age, sex and income underwent an identical acute stress testing procedure. The 
protocol involved tracking participants’ biological responses to stress before, during and up 
to 75 min after undertaking two 5-min standardized stress tasks. The investigators reported 
that people with T2DM experience chronic allostatic load, which manifested as alterations in 
biological responses to acute mental stress. Notably, participants with T2DM displayed 
reduced cardiovascular, neuroendocrine, inflammatory and metabolic responses to acute 
stress, coupled with impaired post-stress recovery. This study was cross-sectional, precluding 
inferences about causality. Therefore, whether heightened allostatic load precedes the 
development of T2DM and is a mechanism through which stress contributes to T2DM risk or 
whether allostatic load is secondary to the dysregulation of glucose metabolism in people 
with T2DM remains unclear.  
  Of note, biological reactivity to stress differs between individuals. The magnitude of the 
stress response and the ability to recover effectively are believed to be determined by 
multiple factors including genetics, personal perception of the specific stressor and coping 
resources60. Whether or not psychological stress promotes incident T2DM or complications 
in those individuals with existing diabetes mellitus will depend on the interaction between an 
individual’s intrinsic stress responsivity and stress exposure in daily life, set against other 
health risk factors.  
 
Stress and health behaviours  
The biological changes that occur as a result of chronic stress do not happen in isolation and 
are often exacerbated by unhealthy behaviours such as poor diet, physical inactivity, smoking 
and reduced adherence to medication13. A detailed examination of this literature is beyond the 
scope of this Review, but it is important to acknowledge that psychological stress might 
decrease motivation for healthy lifestyle behaviours both before and after T2DM onset. For 
example, in a Danish study of over 7,000 initially healthy adults with a 10-year follow-up 
period, perceived stress was linked with physical inactivity and unsuccessful smoking 
cessation or alcohol reduction attempts, as well as T2DM development in men61. In people 
with existing diabetes mellitus, evidence from a meta-analysis indicates that comorbid 
depression increases non-adherence to a range of behaviours including diet, medication usage 
and exercise62. Unhealthy behaviours influence stress-related biological pathways. For 
example, the HPA axis is involved in the regulation of appetite and energy balance, and stress 
is associated with increased food intake in some individuals63. In addition, an inverse 
association between inflammation and physical activity has been reported in people with 
T2DM64; however, more research investigating the potential synergies between behavioural 
and biological pathways is needed to further understand the complex links between 
psychological stress and T2DM.  
 
Psychological stress and T2DM  
Psychological stress comes in three forms; emotional disorders or states of distress such as 
depression and anxiety; personal traits, including anger or hostility; and external stressors, 
such as exposure to stressful conditions in adult or earlier life. A growing body of literature 
indicates that psychological stress might have a role in the development of diabetes mellitus 
in initially healthy populations and could affect outcomes in people with an existing 
diagnosis.  
 
Psychological and social factors and T2DM risk  
Depression is the most commonly researched psychological factor in the diabetes mellitus 
field. Results from meta-analyses and prospective cohort studies indicate that depression is 
associated with an increased risk of diabetes mellitus65–68 (TABLES 1, 2). Depressive 
symptoms, such as loss of pleasure and feelings of hopelessness, and a diagnosis of clinical 
depression are predictive of future development of diabetes mellitus67, 68. Anxiety is not as 
well researched as depression, and reported links with new onset diabetes mellitus have been 
equivocal69–74. Several possible explanations exist for these mixed findings. First, the 
symptoms of depression and anxiety could overlap, and an independent association between 
anxiety and diabetes mellitus might not exist. Second, differences in measurements across 
studies or sex differences in the association might account for the results. Three studies have 
investigated the link between psychological distress and new onset diabetes mellitus. The 
largest study found an association between psychological distress and future development of 
diabetes mellitus, but the finding was attenuated after controlling for health behaviours75. 
Another study only detected the association in a subset of participants who had a high risk of 
developing T2DM at baseline76, whereas a third reported a sex difference in the association, 
with psychological distress predicting new onset T2DM in men but not in women77.  
Most research on external stressors has focused on how measures of work-related 
stress can increase one’s risk of developing T2DM. Meta-analytic evidence indicates that job 
strain, which is defined as high job demands coupled with low control at work, is associated 
with an increased risk of T2DM78 (TABLE 1). Long work hours (≥55 h per week) have also 
been related to increased risk of diabetes mellitus but only in low socioeconomic groups79. 
Perceived stress has been investigated in relation to the development of T2DM in several 
studies61, 80–85. Considering the evidence as a whole, a link seems to exist between perceived 
stress and development of T2DM. However, this association has been shown in some studies 
to vary by sex or socioeconomic status (as measured by occupational status), which indicates 
that these factors might moderate this relationship.  
Little prospective research has investigated the association between diabetes mellitus 
and personality traits (TABLE 2). Two studies have investigated the link between anger as 
assessed by questionnaire (Spielberger Trait Anger Scale) and subsequent development of 
T2DM70, 86. In the Atherosclerosis Risk in Communities Study of 11,615 participants, trait 
anger was associated with an increased risk of future T2DM independent of covariates86. A 
later study of 5,598 individuals also found that this characteristic significantly increased 
T2DM risk; however, statistical adjustment for waist circumference attenuated the 
association70.  
Individuals who report adverse childhood experiences, such as neglect or physical 
abuse, seem to be at increased risk of diabetes mellitus in adulthood (combined odds ratio of 
1.32 (95% CI 1.16–1.51))87. The methodological approaches adopted by researchers in the 
field have varied. In some studies, adult participants recalled early life experiences via self-
report questionnaires, whereas, in others, data were based on review of court records taken 
over an individual’s life course87. Little research has investigated the association between 
potentially protective, positive psychological traits, such as optimism and life satisfaction, 
and T2DM risk. One interesting study of 1.5 million Swedish military recruits with a 25.7 
years of follow-up reported that low stress resilience (as assessed by semi-structured 
interview) was a predictor of the development of T2DM88. This association was robust to 
adjustment for a range of risk factors for T2DM. A 2016 analysis of the English Longitudinal 
Study of Ageing found that high quality of life was associated with a reduced risk of T2DM 
over a 6-year follow-up period in participants who were <65 years of age89. However, the 
evidence for a link between life satisfaction and reduced T2DM risk is weak. In a large 
European cohort, no association between life satisfaction and T2DM risk was detected in 
men, whereas, in women, the relationship did not remain after adjustment for covariates90. An 
analysis of the Whitehall II cohort found no association between optimism, life satisfaction or 
well-being and T2DM risk over 13 years of follow-up91.  
   Taken together, negative psychological factors (for the most part) have been 
prospectively associated with an increased risk of developing T2DM in initially healthy 
individuals; however, more research on positive psychological factors is needed. The most 
convincing evidence in the area of positive psychological factors comes from meta-analytic 
studies of depression and work stress65, 66, 68, 74,78,79,87. Nevertheless, it should be emphasized 
that these studies do not prove causality, and alternative non-causal explanations are 
plausible. In epidemiological studies, covariates are included to limit non-causal explanations 
(TABLES 1, 2); however, adjusting for potentially confounding factors does not exclude the 
possibility that unmeasured or poorly measured factors account for the relationship. 
 
Psychological factors in diagnosed T2DM  
As well as increasing the risk of new onset diabetes in initially healthy populations, a 
growing body of literature indicates that psychological factors such as depression and anxiety 
have a role in the aetiology of T2DM and its complications after the condition has been 
diagnosed.  
 
Prevalence of psychological stress in T2DM.  
The prevalence of many stress-related conditions is increased in people with diabetes 
mellitus, as has been recognized in diabetes mellitus care guidelines92. Depression is notably 
more common in patients with diabetes mellitus than in the general population93–96. Even 
though estimates vary between studies, from 8.7%96 to 17.6%93 depending on the criteria used 
to assess depression (such as depressive symptoms versus major depressive disorder), rates of 
depression are consistently higher among people with diabetes mellitus than in the diabetes-
free population.  
The prevalence of anxiety is also raised in people with diabetes mellitus relative to the 
general population97, 98. As with studies investigating depression, rates vary depending on the 
definition of anxiety, but a 2013 meta-analysis found that individuals with diabetes mellitus 
have a 20% increased risk of having an anxiety disorder and a 48% increased risk of 
experiencing anxiety symptoms98. Growing evidence suggests that one particular type of 
anxiety, post-traumatic stress disorder, is more prevalent in people with T2DM than in 
healthy controls74.  
Diabetes-related distress is another common stress condition. This concept goes 
beyond general low mood and emotional distress and refers to the unique burden of living 
with and managing this chronic condition99. Diabetes-related distress encompasses distress 
related to self-management, regimen adherence and complications associated with diabetes 
mellitus99, 100. A study of almost 9,000 people with diabetes mellitus found that 44.6% report 
considerable diabetes-related distress101.  
Diagnosis with T2DM might also be a prognostic factor for cases of new onset 
depression. A number of prospective studies indicate that diabetes mellitus is a risk factor for 
incident depression66,102,103, with a 25% greater risk of new onset depression in patients with 
diabetes mellitus than in controls102. However, it should be noted that the increased risk of 
depression in response to a disease diagnosis is not exclusive to diabetes mellitus and that this 
relationship has been observed in many other chronic conditions104.  
 
Psychological factors and disease management in T2DM.  
Comorbid depression can negatively affect quality of life in people with T2DM105, 106. 
Depression in diabetes mellitus affects the patient’s ability to control the disease, as well as 
self-care behaviours. For example, depression has been associated with suboptimal 
glycaemic control in people with diabetes mellitus, with stronger effects observed in patients 
with interview-diagnosed depression than in patients with self-reported depression107. A 2008 
meta-analysis that included both cross-sectional and longitudinal evidence found that 
depression was associated with non-adherence to various treatment regimens62. Longitudinal 
research published after this meta-analysis has also reported poorer treatment adherence in 
people with diabetes mellitus and depressive symptoms108. 
    The clinical significance of diabetes-related distress is exemplified by its association 
with poor glycaemic control and the greater effect that it has on glycaemic management 
compared with depression99, 109. Diabetes-related distress can also predict medication 
adherence in T2DM109, such that those with greater levels of distress have poorer medication 
adherence.  
Few studies have looked at the relationship between anxiety and self-care behaviours 
in T2DM; however, it is worth noting that fear of hypoglycaemia, as well as anxiety 
regarding glucose-lowering treatments, is commonly observed in around 25% of patients110. 
This form of anxiety can manifest as non-adherence to medication resulting in poor 
glycaemic control and raised levels of glucose110. One early meta-analysis of cross-sectional 
studies reported an inverse association between anxiety and poor glycaemic control111. 
Longitudinal research is lacking, but subsequent research in small cross-sectional studies has 
generally supported a link between anxiety and worse glucose control112–114, and one 
prospective study of 1,691 individuals related anxiety to functional disability in T2DM115.  
    Limited research has investigated the relationship between potentially protective 
psychological factors and glycaemic control in people with T2DM, and most research has 
been cross-sectional. One prospective study of 97 elderly women looked at the relationship 
between positive well-being (as defined by questionnaire measures of positive affect, purpose 
in life and personal growth) and glycaemic control116. Those with greater positive well-being 
at baseline had significantly lower levels of HbA1c at 2-year follow-up adjusting for age, 
income, marital status, waist–hip ratio and statin usage than those with lower positive well-
being. Unfortunately, the significance of this finding is limited because the study did not 
include people with T2DM. The longitudinal relationship between resilience (the ability to 
maintain psychological well-being in situations of adversity) and glycaemic control was 
assessed in a study of 111 individuals with either T1DM or T2DM117. In this study, low stress 
resilience was associated with worsening levels of HbA1c over the 1-year follow-up period in 
both types.  
Taken together, these data suggest that depression and diabetes-related distress are 
associated with glycaemic control and treatment adherence in T2DM. The use of cross-
sectional studies and small sample sizes has limited the research on anxiety and potentially 
protective psychological factors.  
 
Psychological factors and complications  
Chronic hyperglycaemia is associated with long-term damage in multiple systems. The 
harmful effects of T2DM include microvascular (damage to the small blood vessels) and 
macrovascular (damage to the large blood vessels) complications. Microvascular compli-
cations include retinopathy (which can lead to blindness), nephropathy (which can lead to 
renal failure) and neuropathy (which can lead to impotence, foot ulcers and amputation) 46. 
The macrovascular complications of T2DM include various cardiovascular diseases118. 
Emerging evidence suggests that psychological factors might increase the risk of 
complications resulting from T2DM (TABLES 3, 4).  
   The most commonly researched psychological factor in the context of complications 
resulting from T2DM is depression. Prospective evidence indicates that patients with a 
diagnosis of T2DM and depression have an increased risk of a myriad of microvascular 
complications, including foot ulcers, retinopathy and chronic kidney disease119–123, as well as 
macrovascular complications, such as myocardial infarction and stroke121, 124–127. Depression 
in T2DM is associated with an increased risk of cardiovascular and all-cause mortality128–130. 
A limited number of studies have assessed the association between anxiety and T2DM 
complications but have failed to detect an association131, 132. One study looked at 
psychological distress and outcomes in T2DM and found that psychological distress 
predicted cardiovascular and all-cause mortality133. With regard to positive psychological 
traits, one study assessed positive well-being and risk of mortality in people with diabetes 
mellitus over a 10-year follow-up period134, but protective effects did not remain once 
covariates were taken into consideration. Nevertheless, sub-analyses from this study indicated 
that enjoyment of life (a component of positive affect) reduced the risk of mortality in people 
with diabetes mellitus.  
 
Stress modification in T2DM  
If stress is relevant to T2DM, does stress management or stress modification have a 
therapeutic benefit? One study reported that group-based stress management training for 
people with T2DM could improve glycaemic control over a 1-year follow-up period135. A 
2016 randomized control trial (RCT) including US-based Latino people found that stress 
management improved self-reported depression, anxiety and self-rated health scores; how-
ever, the intervention and control groups did not differ in levels of HbA1c at 3-month follow-
up136. Some evidence suggests that cognitive behavioural interventions and self-management 
programmes improve diabetes-related distress137, 138, but reducing diabetes-related distress 
might not result in improvements in levels of HbA1c or inflammatory markers137, 138.  
    Mindfulness has also been applied in an attempt to modify psychological stress in 
people with T2DM and seems to reduce symptoms of depression, anxiety, general stress and 
diabetes-related stress. A systematic review of the effectiveness of mindfulness-based inter-
ventions on glycaemic control identified seven studies: four interventions were found to 
improve levels of HbA1c, but the remaining three studies, which had larger sample sizes, 
reported no effect139. As mindfulness-based interventions for T2DM are fairly new, more 
studies with longer follow-up periods are needed to fully understand how this intervention 
affects glucose control.  
The bulk of research on stress modification in T2DM has assessed whether treating 
depression in patients with T2DM improves psychological and physical outcomes. A 2012 
Cochrane Review assessed the results from 19 RCTs of pharmacological and psychological 
interventions for depression in diabetes mellitus140. Antidepressant usage (including selective 
serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants) as a pharmacological 
intervention had a moderate effect on short-term (defined as end of treatment) depression 
severity, as well as depression remission. In addition, antidepressant usage notably improved 
glycaemic control at the end of the study period. Most pharmacological RCTs used SSRIs as 
a therapy, and, in sensitivity analyses, the associations remained when only these studies 
were included. Psychological interventions including cognitive behavioural therapies and 
psychodynamic supportive therapies improved depression severity and had a beneficial effect 
on depression remission at the end of the study period and up to 6 months later; however, it 
was unclear whether psychological intervention was beneficial for glycaemic control as the 
study findings were mixed.  
    The gold standard for the management of comorbid depression in adults with chronic 
disease is collaborative care141. A 2014 meta-analysis pooled the results from seven RCTs of 
collaborative care for patients with depression and diabetes mellitus142. The results suggest 
that collaborative care reduces depression scores and levels of HbA1c in people with diabetes 
mellitus. However, the reductions in depression severity were not correlated with reductions 
in levels of HbA1c. The authors of the meta-analysis suggest that collaborative care for 
depression in diabetes mellitus could improve glucose control through other means, such as 
improved self-management, independent of depression.  
    Taken together, these findings indicate that therapies to modify psychological factors 
in people with diabetes mellitus have been reasonably effective in reducing the severity of 
depression and diabetes-related distress, but evidence for an effect on glycaemic control is 
mixed. Treating patients with comorbid T2DM and depression with antidepressants improves 
glycaemic control in the short term, and collaborative care is beneficial for reducing levels of 
HbA1c. However, the reductions reported in the severity of depression following collab-
orative care were not statistically significantly associated with reductions in HbA1c.  
    The evidence linking mindfulness-based intervention with improvements in levels of 
HbA1c is mixed. To our knowledge, no studies have assessed the effect of psychological 
stress modification on the microvascular and macrovascular complications that are associated 
with T2DM. As hyperglycaemia is linearly associated with increased cardiovascular disease 
risk143, 144, interventions that improve glycaemic control might also affect hard clinical 
outcomes, but this effect remains to be tested. Links between psychological interventions and 
the biological pathways detailed earlier in this Review have yet to be explored in detail.  
 
Conclusion  
Emerging evidence from animal studies, epidemiological studies and human laboratory stress 
trials indicates that stress-related biology is altered in T2DM and that disturbances across 
multiple biological systems reflecting chronic allostatic load might be present. Most of the 
evidence linking biological stress processes comes from observational studies, so we are 
unable to draw causal conclusions. Accumulating evidence, for the most part, has linked 
various psychological stress factors with new onset T2DM. Comorbid depression in T2DM 
increases the risk of early onset and progression of microvascular and macrovascular 
complications and increases mortality. Various interventions to improve symptoms of 
depression and diabetes-related distress seem to have a favourable impact on these outcomes. 
The effect of these interventions on glycaemic control is less certain, and research on the 
effect of stress modification on complications in T2DM is lacking. 
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Review criteria  
We searched for articles on PubMed, focusing where possible on prospective studies and 
meta-analyses published up until November 2016. The following terms were used to obtain 
the literature on the biological aspects of stress in diabetes: “stress” and “blood pressure”, 
“heart rate”, “cardiovascular”, “cortisol”, “glucocorticoid”, “inflammation”, “inflammatory” 
“allostatic’, together with “diabetes” and “type 2 diabetes”. The following terms were used to 
obtain the literature on the link between psychological stress and diabetes: “stress”, “depres-
sion”, “depressive”, “anxiety”, “distress”, “work stress”, “job strain”, “hostility”, “anger”, 
“optimism” together with “diabetes”, “type 2 diabetes” and “prospective”. In addition, we 
scrutinized the reference sections of all articles. The papers included are all full-text, English-
language papers. 
 
Glossary 
 
Psychological stress: A broad term referring to a range of psychological phenomena 
including exposure to external challenges (stress conditions in adult or earlier life), 
psychological distress (including depression and anxiety) and personal traits, such as anger or 
hostility.  
 
Diurnal cortisol pattern: The distinct pattern of daily cortisol output in humans  
Adipokines: An umbrella term for inflammatory factors expressed in adipose tissue.  
 
The metabolic syndrome: A combination of factors (including central obesity, raised blood 
pressure and raised cholesterol levels) that increases the risk of type 2 diabetes mellitus.  
 
Psychological distress: A measure that encompasses depressive symptoms, anxiety, general 
stress and sleep disturbance.  
 
Self-care behaviours: In type 2 diabetes mellitus these include behaviours such as glucose 
monitoring, managing complications and adhering to medication and lifestyle 
recommendations.  
 
Collaborative care: A multidisciplinary form of management that can include a combination 
of lifestyle, pharmacological and psychological therapies as well as patient education and 
regular practitioner monitoring.  
 
 
 
 
Table 1 | Meta-analyses linking psychological factors with T2DM risk 
Population (sample 
size, follow-up) 
Psychological 
measure 
Association with T2DM risk  
 
Refs 
Nine studies 
(n = 174,035; 
average 9.4 year 
follow-up) 
Depression *RR 1.37 (95% CI 1.14–1.63). Knol (2006)59 
13 studies (n = 6,916 
incident cases of 
diabetes mellitus; 
average 9.4 year 
follow-up) 
Depression *RR 1.60 (95% CI 1.37–1.88). Mezuk 
(2008)60 
23 studies 
(n = 19,977 incident 
cases of diabetes 
mellitus, average 8 
year follow-up) 
Depression *Unadjusted RR 1.56 (95% CI 
1.37–1.77) 
Adjusted RR 1.38 (95% CI.23–
1.55). 
Rotella 
(2013)62 
Five studies (four 
longitudinal; healthy 
n = 125,723, PTSD 
(n = 23,203)  
 
PTSD *RR1.49 (95% CI 1.17–1.89). Vancampfort 
(2016)68 
13 European studies 
(n = 124,808; 
n = 3703 incident 
cases of diabetes 
mellitus; 10.3 year 
follow-up) 
Work stress defined 
by job strain 
*HR 1.15 (95% CI 1.06–1.25). Nyberg 
(2014)72 
19 cohort studies 
from the USA, 
Europe, Japan and 
Australia 
Work stress defined 
by long working 
hours >55 h a week 
‡Association only in low SES 
groups 
RR 1.29 (95% CI 1.06–1.57). 
Kivimäki 
(2015)73 
(n = 222,120, 
n = 4,963 incident 
cases of diabetes 
mellitus; average 7.6 
year follow-up) 
Seven studies, four 
prospective 
(n = 87,251, 
n = 5,879 incident 
cases of diabetes 
mellitus) 
Adverse childhood 
experiences 
*OR 1.32 (95% CI 1.16 –1.51). Huang 
(2015)81 
*positive association; ‡some association; §no association. CI, confidence interval; HR, hazard ratio; OR, odds 
ratio; PTSD, post-traumatic stress disorder; RR, relative risk.  
 
Table 2 | Prospective studies linking psychological factors with T2DM risk 
 
Population (sample 
size, follow-up) 
Psychological measure Association with 
diabetes mellitus risk 
 
Refs 
ELSA cohort 
(n = 4,238; 6 year 
follow-up) 
Depressive symptoms 
using the eight-item centre 
for epidemiologic studies-
depression scale (CES-D) 
OR 1.53 (95% CI 0.80-
2.93)*. 
Demakakos (2014)61 
Norwegian cohort (n = 
37,291; 10 year follow-
up) 
Anxiety using the hospital 
anxiety and depression 
scale, seven-items for 
anxiety 
OR 1.5 (95% CI 1.3–
1.8)‡ 
Did not control for 
depression. 
Engum (2007)63 
NESDA cohort (n = 
2,460; 2 year follow-
up) 
Anxiety using composite 
interview diagnostic 
instrument 
OR 1.6 (95% CI 1.2–
2.1). 
Atlantis (2012)66 
US adults (n=1920; 11 
year follow-up) 
Anxiety using the 
Diagnostic Interview 
Schedule 
§OR 1.00 (95% CI 
0.53–1.89). 
Edwards (2012)126 
3 prospective cohorts; 
Health Professional’s 
follow-up study (n = 
30,791 men); Nurses’ 
Health Study (n = 
68,904 women); 
Nurses’ Health Study 
II (n = 79,960 women). 
Total n = 12,831 
incident cases, 18–20 
years follow-up 
Phobic anxiety symptoms 
using the eight-item 
Crown–Crisp index 
‡No association in the 
male cohort after 
adjustment in Health 
Professional’s follow-up 
study but associations 
reported in women. In 
the Nurses’ Health 
Study  
HR 1.02 (95% CI 1.01–
1.03). In the Nurses’ 
Health Study II  
HR 1.04 (95% CI 1.02–
1.05). 
Farvid (2014)65 
Two prospective 
cohorts; NHANES 
cohort (n = 3,233; 17 
year follow-up); The 
Detroit Neighbourhood 
Study (n = 1,054; 18 
year follow-up) 
 
Anxiety using the 
generalized anxiety 
disorder-seven item 
questionnaire 
‡No association in the 
overall sample. 
Dividing the groups by 
sex, in both studies 
association found in 
women only. 
In the NHANES cohort, 
RR 2.19 (95% CI 1.17–
4.09) 
In the Detroit 
Neighbourhood Study, 
RR 1.62 (95% CI 0.61–
4.32). 
Demmer (2015)67 
MESA cohort (n = 
5,598; 11.4 year 
follow-up) 
Anxiety using the 
Spielberger trait anxiety 
scale 
§HR 1.16 (95% CI 
0.87–1.54). 
Abraham (2015)64 
Swedish adults (n = 
5,227; 8–10 year 
follow-up) 
Psychological distress 
using an index of five 
questions on anxiety, 
apathy, depression, fatigue 
and insomnia 
‡Association only in 
males 
OR 2.2 (95% CI 1.2–
4.1). 
Eriksson (2008)71 
UK adults (n = 9,514; 
18 year follow-up) 
Psychological distress 
using the 12- item general 
health questionnaire  
*HR 1.33 (95% CI 
1.10–1.61). Attenuated 
controlling for health 
behaviours.  
Mommersteeg (2012)69 
Whitehall cohort (n = 
5,932; average follow-
up 5.46 years) 
Psychological distress 
using the 30-item general 
health questionnaire 
‡No association in the 
overall sample, only in 
those at high risk of 
diabetes mellitus at 
baseline  
OR 2.07 (95% CI 1.19–
3.62). 
Virtanen (2014)70 
Japanese men (n = 128; 
mean follow-up 3.2 
years) 
Perceived stress using 15-
item stress in daily life 
questionnaire developed 
for Japanese individuals 
*HR 3.81 (95% CI 
1.09–13.35). 
Toshihiro (2008)75 
Danish adults (n = 
7,066; 10 year follow-
up) 
Perceived stress intensity 
on seven-point scale (one-
item) and stress frequency 
on seven-point scale (one-
item). 
‡Association only in 
men OR 2.36 (95% CI 
1.22– 4.59). 
Rod (2009)55 
Japanese adults (n = 
55,826, n = 1,601 
incident cases of 
diabetes mellitus; 10 
year follow-up) 
Perceived stress based on 
one item ‘How much stress 
to feel in daily life?’ (three 
point scale) 
*Overall association but 
effects were stronger 
among male OR 
1.39(95% CI 1.15–1.65) 
than in female 
participants OR 1.25 
(95% CI 1.01-1.56 ). 
Kato (2009)77 
Australian adults (n = 
3,759; 5 year follow-
up) 
Perceived stress in 30-item 
questionnaire  
‡Outcome was abnormal 
glucose tolerance rather 
than overt diabetes 
mellitus. Association 
only in women OR 1.72 
(95% CI 1.07-2.76).  
Williams (2013)76 
Swedish men (n = 
7,251; n = 899 incident 
cases of diabetes 
mellitus; 35 year 
follow-up) 
Perceived permanent stress 
(self-reported stress related 
to work or home life 
ongoing for >1 year) 
*HR 1.52 (95% CI 
1.26–1.82). 
Novak (2013)74 
French adults (n = 
22,567, n=527 incident 
cases of diabetes 
mellitus; 5.3 year 
follow-up) 
Perceived stress using the 
four-item perceived stress 
Scale  
‡Association only in 
those of low 
occupational status  
OR 1.39 (95% CI 1.02–
1.90). 
Wiernik (2016)78 
Israeli defence forces 
(n = 32,584 men, n = 
723 incident cases of 
diabetes mellitus; mean 
follow-up 6.3 years ) 
Perceived emotional 
distress based on one item 
‘Are you preoccupied by 
worries or concerns that 
affect your overall 
wellbeing?’ 
*HR 1.53(95% CI 1.08– 
2.18). 
Twig (2016)79 
Danish cohort (n = 1.9 
million, n = 45,302 
who experienced pre-
natal stress)  
Pre-natal stress measured 
by mother’s experience of 
bereavement  
*Incidence rate ratio 
1.31 (95% CI 1.01–
1.69). 
Virk (2012)139 
ARIC cohort (n = 
11,615; 6 year mean 
follow-up) 
Anger using the 
Spielberger trait anger 
scale (ten item) 
 
*HR 1.34 (95% CI 
1.10– 1.62). 
Golden (2006)80 
MESA cohort (n = 
5,598; 11.4 year mean 
follow-up) 
Anger using the 
Spielberger trait anger 
scale 
 
*The trait anger HR 
1.48 (95% CI 1.04–.12). 
Attenuated after 
adjustment for waist 
circumference.  
Analysis of the 
Spielberger anger 
reactivity sub-scale HR 
1.07 (95% CI 1.03–
1.11) robust to all 
covariates. 
 
Abraham (2015)64 
Swedish male military 
conscripts (n = 1.5 
million; average mean 
follow-up 25.7 years) 
Low stress resilience 
assessed by semi-
structured interview 
*HR 1.51 (95% CI 
1.46–1.57). 
Crump (2016)82 
EPIC cohort (n = 
50,358, n incident 
Life satisfaction assessed 
with one item ‘how 
§Women with high life 
satisfaction had reduced 
Feller (2013)84 
diabetes = 1840; 
average mean follow-
up 8 years) 
satisfied are you with your 
life?’ 
risk of diabetes mellitus 
1.53 (95% CI 1.19–
1.97). Not robust to 
adjustment for 
covariates. (95% CI 
1.27 (0.98–1.64)). No 
associations in men.  
Whitehall cohort (n = 
7800; 13 year mean 
follow-up ) 
• Life satisfaction 
measured by self-
report satisfaction 
with seven life 
domains. 
• Emotional vitality 
measured using 
three items from 
the Short-form 36 
• Optimism 
measured using 
one item “Over 
the next 5–10 
years, I expect to 
have many more 
positive than 
negative 
experiences” (six 
point scale)  
‡No associations in 
overall sample. Sub-
analyses by diabetes 
mellitus type (doctor 
diagnosed or 
Whitehall assessment) 
people with high life 
satisfaction OR 
0.85(95% CI 0.76–0.95) 
and emotional vitality 
OR 0.86 (95% CI 0.77–
0.97) were less likely 
to report doctor-
diagnosed diabetes 
mellitus.  
Boehm (2015)85 
ELSA (n = 8,182 and n 
= 451 new cases of 
diabetes mellitus; 
median mean follow-
up of 6 year) 
CASP-19 quality of life 
scale.  
 
‡Greater quality of life 
was associated with 
decreased diabetes 
mellitus risk HR 0.82 
(95% CI 0.70–0.95) but 
only in those aged <65 
years. 
Okely (2016)83 
 
*positive association; ‡some association; §no association. ARIC, Atherosclerosis Risk in Communities Study; 
CASP, Control, Autonomy, Self-realisation and Pleasure; CES-D, Centre for Epidemiologic Studies-Depression 
scale; CI, confidence interval; ELSA, English Longitudinal Study of Ageing; EPIC, European Prospective 
Investigation into Cancer and Nutrition; HR, hazard ratio; MESA, Multi-Ethnic Study of Atherosclerosis; 
NESDA, Netherlands Study of Depression and Anxiety; NHANES, National Health and Nutrition Examination 
Survey; OR, odds ratio; RR, relative risk; SES, socioeconomic status.  
  
Table 3 | Meta-analyses linking psychological factors with incident microvascular and 
macrovascular complications in diabetes mellitus 
 
Population (sample 
size, follow-up) 
Psychological measure Association with 
diabetes mellitus 
complications and 
mortality 
 
Refs 
27 cross-sectional 
studies (n = 5374) 
 
Depression *Depression associated 
with retinopathy, 
nephropathy, 
neuropathy, sexual 
dysfunction and 
macrovascular 
complications. Effect 
size small to moderate 
(r = 0.17–0.32). Limited 
by lack of prospective 
evidence and the 
inclusion of studies of 
both T1DM and T2DM.  
De Groot (2001)140 
13 cross-sectional 
studies (n = 3,898 with 
diabetes mellitus) 
 
Depression *Depression in diabetes 
mellitus associated with 
neuropathy OR 2.01 
(95% CI 1.60–2.54). 
Limited by use of cross-
sectional evidence.  
Bartoli (2016)141 
16 prospective studies 
(eight studies on 
T2DM); 6 year follow-
up. (n = 109,046 with 
diabetes mellitus; n = 
21,443 with diabetes 
mellitus and 
depression).  
Depression *Increased risk of all-
cause mortality HR  
1.46 (95% CI  1.29–
1.66). Increased risk of 
cardiovascular mortality  
HR  1.39 (95% CI  
1.11–1.73). 
Van Dooren (2013)123 
16 prospective studies 
(nine studies on 
T2DM); 6 year follow-
up (n = 107,944 with 
diabetes mellitus; n = 
19,589 with diabetes 
mellitus and 
depression). 
Depression by self-report 
and by clinical interview 
*Self-reported 
depression: increased 
risk of all-cause 
mortality HR  1.76 
(95% CI 1.45–2.14).  
Clinically diagnosed 
depression: increased 
risk of all-cause 
mortality HR  1.49(95% 
CI 1.15–1.93)  
Hofmann (2013)124 
Ten prospective studies 
(n = 42,363 with 
diabetes mellitus; n = 
5,325with diabetes 
Depression *Increased risk of 
mortality HR 1.50 (95% 
CI 1.35–1.66) 
Park (2013)122 
mellitus and 
depression). 2–10 year 
follow-up. 
 
Studies of both T1DM 
and T2DM included. 
*positive association; ‡some association; §no association. CI, confidence interval; HR, hazard ratio; OR, odds 
ratio; PTSD, post-traumatic stress disorder; r, correlation coefficient; RR, relative risk; T1DM, type 1 diabetes 
mellitus; T2DM, type 2 diabetes mellitus. 
  
Table 4 | Prospective studies linking psychological factors with incident microvascular 
and macrovascular complications in diabetes mellitus  
 
Population (sample 
size, follow-up) 
Psychological measure Association with 
diabetes mellitus 
outcome  
 
Refs 
Americans of Mexican 
origin (n = 2,830, 23% 
with diabetes); 7 year 
follow-up 
Depressive symptoms 
measured by CES-D, 
clinical depression 
assessed by diagnostic 
interview 
*Depressive symptoms 
and major depression 
associated with 
increased risk 
microvascular and 
macrovascular 
complications of 
diabetes mellitus as well 
as mortality.  
 
Black (2003)142 
Pathways 
Epidemiological 
Follow-up study (n = 
3,473 with diabetes 
mellitus; mean follow-
up 4.1 years) 
Depressive symptoms 
assessed by the PHQ-9 
*Major depression 
associated with 
increased risk of 
incident diabetic foot 
ulcers 2.00 (95% CI, 
1.24–3.25). No 
association with minor 
depressive symptom.  
Williams (2010)113 
Pathways 
Epidemiological 
Follow-up study (n = 
4,623 with diabetes 
mellitus;  5 year 
follow-up) 
Depressive symptoms 
assessed by the PHQ-9 
*Major depression 
associated with 
increased risk of 
microvascular HR 1.36 
(95% CI 1.05–1.75) and 
macrovascular 
outcomes HR1.24 (95% 
CI 1.0 –1.54). 
Lin (2010)120 
UK and USA 
collaborative study;  n 
= 333 with peripheral 
neuropathy (73% with 
T2DM) 18 month 
follow-up  
Depression assessed by the 
HADS 
‡Increased risk of first 
diabetic foot ulcer HR 
1.68 (95% CI 1.20–
2.35). No association 
for recurrent ulceration. 
Study limited by use of 
sample with existing 
peripheral neuropathy. 
Gonzalez (2010)116 
Pathways 
Epidemiological 
Follow-up study ( n= 
2,359 with diabetes 
mellitus; 5 year follow-
up) 
Depressive symptoms 
assessed by the PHQ-9 
*Increased risk of 
incident retinopathy OR 
1.03 (95% CI 1.01–
1.05). 5 point increase 
on PHQ-9, 15% 
increased risk of 
retinopathy. 
Sieu (2011)114 
US Veterans n = 345, Diagnosed major *Patients with diabetes Scherrer (2011)119 
949 (depression and 
diabetes free n = 
214,749; depression 
only n = 77,568; 
diabetes mellitus only 
n = 40,953; depression 
and diabetes mellitus n 
=12,679; 7 year 
follow-up) 
depressive disorder 
 
 
 
mellitus and depression 
had an 83% increased 
for myocardial 
infarction HR 1.82 
(95% CI 1.69–1.97). 
Chinese adults with 
diabetes mellitus n = 
7,835; 7.4 year follow-
up). 
Depression assessed by 
psychiatrist diagnosis 
*Increased risk of CVD 
HR 2.18 (95% CI 1.45– 
3.27), sub-analysis 
indicated stroke 
accounted for most of 
the risk HR 3.55 (95% 
CI 2.15– 5.84). 
Ting (2013)118 
Norwegian adults (n = 
36,031; n = 1,331with 
diabetes mellitus and 
foot ulcer; mean 
follow-up 7.6 years) 
 
Depression assessed by the 
HADS 
‡Depression increased 
risk of foot ulceration 
*HADS score 8-10 
OR1.95 (95% CI 1.02–
3.74); HADS score ≥11 
OR 3.06 (95% CI, 1.24–
7.54). 
Iversen (2015)117 
US veterans (n = ~3 
million, n = 933.211 
with diabetes mellitus ) 
The median follow-up 
was 2,659, 2,916, 2,451, 
and 2,453 days for 
chronic kidney disease, 
mortality, coronary heart 
disease, and stroke, 
respectively. 
Depression assessed by 
clinical diagnosis or anti-
depressant usage 
Depression associated 
with increased risk of 
chronic kidney disease 
HR 1.20 (95% CI 1.19–
1.20); coronary heart 
disease HR 1.22 (95% 
CI 1.19–1.24); stroke 
HR 1.32 (95% CI 1.28–
1.36); all-cause 
mortality HR 1.25 (95% 
CI 1.24–1.26). 
Novak (2016)115 
 
 
 
 
Swedish drug register 
(n = ~4 million; 
depression and 
diabetes n = 47,856; 3 
year follow-up). 
Depression assessed by 
anti-depressant usage 
*Sex stratified analysis 
of risk of myocardial 
infarction. Women HR 
7.4 (95% CI 6.3–8.6). 
Men HR 3.1 (95% CI 
2.8–3.6). Study limited 
by lack of information 
on BMI, smoking or 
lipids. 
Radholm (2016)121 
US adults REGARDS 
cohort (n = 22,003; n = 
4,090 with diabetes 
mellitus; 5.95 year 
follow-up) 
Depressive symptoms 
assessed by the CES-D 
(four item questionnaire) 
and perceived stress 
assessed by Cohen 
Perceived Stress Scale 
(four item questionnaire) 
‡Depressive symptoms 
or perceived stress 
increased risk of stroke 
(HR 1.57; 95% CI 1.–
2.33) and myocardial 
infarction (HR 1.57; 
95% CI 1.02–2.40) and 
CVD death (HR 1.53; 
95% CI 1.08–2.17. 
Cummings (2016)143 
Association for 
myocardial infarction 
attenuated when 
adjusting for health 
behaviours. Limited by 
assessing depressive 
symptoms and 
perceived stress 
together. 
Baltimore 
Epidemiologic 
Catchment Area Study 
(n = 1,920; 8.6% had 
diabetes mellitus and 
anxiety; 11 year 
follow-up) 
Anxiety assessed by 
diagnostic interview 
§No statistically 
significant relationship 
between anxiety and 
incident diabetes 
complications (OR 2.02; 
95% CI 0.61–6.74).  
Edwards (2012)126 
Norwegian adults with 
diabetes mellitus n = 
948. 17 years follow-
up; mean follow-up 12 
years. Participants 
were insulin naive. 
Anxiety symptoms 
assessed by the HADS 
 
Depression symptoms 
assessed by the HADS 
‡Anxiety not associated 
with mortality HR 0.73 
(95% CI 0.50–1.07). 
Depression associated 
with increased mortality 
risk HR 1.39 (95% CI 
1.05–1.84). Depressive 
and anxiety symptoms 
together were not 
associated with 
mortality HR 1.30 (95% 
CI 0.96–1.74). 
Iversen (2016)125 
Australian adults with 
diabetes n = 1,337. 4 
year follow-up. 
Depression assessed by the 
PHQ 
 
Anxiety assed by the 
Generalised Anxiety 
Disorder scale.  
‡Major depression 
increased risk of CVD 
events HR 2.10 (95% CI 
1.22–3.62) and 
cardiovascular mortality 
HR 3.56 (95% CI 1.03–
12.35). Anxiety disorder 
predicted cardiovascular 
mortality HR 5.92; 
(95% CI 1.84–19.08) 
but not CVD events.  
Combined outcome 
major anxious 
depression predicted 
CVD events HR 1.90 
(95% CI 1.11–3.25) and 
cardiovascular mortality 
HR 4.32(95% CI 1.35–
13.86).  
Bruce (2016)144 
Danish adults with 
diabetes (n = 1,533; 
average follow-up 5.4 
years). 
Psychological distress 
measured with the MHI-5 
*Increased risk of a 
CVD event HR 1.69 
(95% CI 1.05–2.70) and 
increased risk of all-
cause mortality HR 1.76 
Dalsgaard (2014)127 
(95% CI 1.23–2.53) 
NHEFS cohort n = 
3,388 (n = 715 with 
diabetes mellitus); 10 
year follow-up 
Positive affect sub-scale of 
the CES-D (assessed by 
four components: self-
esteem; hopeful; happy; 
and life enjoyment) 
‡Positive affect reduced 
risk of mortality HR 
0.87 (95% CI 0.76– 
0.99). Not robust to 
adjustment for 
covariates. Sub-analysis 
of the positive affect 
scale only enjoyment of 
life was a significant 
predictor of reduced 
mortality controlling for 
covariates HR  0.89 
(95% CI 0.79–0.99). 
Moskowitz (2008)128 
 
*positive association; ‡some association; §no association. CES-D, Center for Epidemiologic Study of 
Depression; CI, confidence interval; CVD, Cardiovascular Disease; HADS, Hospital Anxiety and Depression 
Scale; HR, hazard ratio; MHI-5, Mental Health Inventory 5; NHEFS=  NHANES I Epidemiologic Follow-up 
Study PHQ-9, Patient Health Questionnaire; REGARDS, Reasons for Geographic And Racial Differences in 
Stroke; T2DM, type 2 diabetes mellitus. 
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